| The Identification of Seniors at Risk (ISAR) score to predict clinical outcomes and health service costs in older people discharged from UK acute medical units J Edmans, L Bradshaw, JRF Gladman, M Franklin, V Berdunov, R Elliott, ... Age and ageing 42 (6), 747-753, 2013 | 131 | 2013 |
| The future incidence, prevalence and costs of stroke in the UK D King, R Wittenberg, A Patel, Z Quayyum, V Berdunov, M Knapp Age and ageing 49 (2), 277-282, 2020 | 121 | 2020 |
| Estimated societal costs of stroke in the UK based on a discrete event simulation A Patel, V Berdunov, Z Quayyum, D King, M Knapp, R Wittenberg Age and ageing 49 (2), 270-276, 2020 | 119 | 2020 |
| Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study L Tanajewski, R Harris, DJ Harman, GP Aithal, TR Card, G Gkountouras, ... BMJ open 7 (6), e015659, 2017 | 69 | 2017 |
| Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic … J Waugh, R Hooper, E Lamb, S Robson, A Shennan, F Milne, C Price, ... Health technology assessment (Winchester, England) 21 (61), 1, 2017 | 61 | 2017 |
| Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre international trial of cardiac … MR Edwards, G Forbes, N MacDonald, V Berdunov, B Mihaylova, P Dias, ... BMJ open 9 (1), e023455, 2019 | 55 | 2019 |
| Current, future and avoidable costs of stroke in the UK A Patel, V Berdunov, D King, Z Quayyum, R Wittenberg, M Knapp Stroke Association, 2017 | 40 | 2017 |
| Identifying patient-level health and social care costs for older adults discharged from acute medical units in England M Franklin, V Berdunov, J Edmans, S Conroy, J Gladman, L Tanajewski, ... Age and ageing 43 (5), 703-707, 2014 | 26 | 2014 |
| Executive summary part 2: burden of stroke in the next 20 years and potential returns from increased spending on research A Patel, V Berdunov, D King, Z Quayyum, R Wittenberg, M Knapp London: Stroke Association, 2017 | 22 | 2017 |
| Economic evaluation of a general hospital unit for older people with delirium and dementia (TEAM randomised controlled trial) L Tanajewski, M Franklin, G Gkountouras, V Berdunov, RH Harwood, ... PLoS One 10 (12), e0140662, 2015 | 22 | 2015 |
| Cost-effectiveness of a specialist geriatric medical intervention for frail older people discharged from acute medical units: economic evaluation in a two-centre randomised … L Tanajewski, M Franklin, G Gkountouras, V Berdunov, J Edmans, ... PloS one 10 (5), e0121340, 2015 | 22 | 2015 |
| Medical crises in older people: cohort study of older people attending acute medical units, developmental work and randomised controlled trial of a specialist geriatric medical … J Gladman, R Harwood, S Conroy, P Logan, R Elliott, R Jones, S Lewis, ... Programme Grants for Applied Research 3 (4), 1-410, 2015 | 17 | 2015 |
| Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer V Berdunov, S Millen, A Paramore, P Hall, T Perren, R Brown, J Griffin, ... Journal of Medical Economics 25 (1), 591-604, 2022 | 15 | 2022 |
| Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT SCL Hewer, AR Smyth, M Brown, AP Jones, H Hickey, D Kenna, D Ashby, ... Health Technology Assessment 25 (65), 1-+, 2021 | 13 | 2021 |
| OPTIMISE II investigators. Optimisation of Perioperative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) trial: study protocol for a multicentre … MR Edwards, G Forbes, N MacDonald, V Berdunov, B Mihaylova, P Dias, ... BMJ Open 9 (1), e023455, 2019 | 7 | 2019 |
| Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer V Berdunov, S Millen, A Paramore, J Griffin, S Reynia, N Fryer, R Brown, ... ClinicoEconomics and Outcomes Research, 448-633, 2022 | 4 | 2022 |
| The budget impact of utilizing the Oncotype DX Breast Recurrence Score test from a US healthcare payer perspective V Berdunov, E Laws, G Cuyun Carter, R Luo, C Russell, S Campbell, ... Journal of Medical Economics 26 (1), 973-990, 2023 | 3 | 2023 |
| EE382 Cost-Utility Analysis of Avacopan for the Treatment of Anca-Associated Vasculitis (AAV) Patients in the UK AR de Arellano Serna, V Berdunov, G Baxter Value in Health 25 (12), S130, 2022 | 2 | 2022 |
| HSR22-129: The Cost of Treatment of HR+/HER2-Early Breast Cancer and Implications for the Cost-Effectiveness of Multigene Assays in the US V Berdunov, GC Carter, E Laws, R Luo, C Russell, S Campbell, Y Abdou, ... Journal of the National Comprehensive Cancer Network 20 (3.5), HSR22-129 …, 2022 | 2 | 2022 |
| Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial. V Berdunov, S Millen, A Paramore, S Reynia, N Fryer, J Griffin, N Georges Journal of Clinical Oncology 39 (15_suppl), 534-534, 2021 | 2 | 2021 |
